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Abstract
Introduction: Drugs that counteract nociceptive transmission in the spinal dorsal horn preferentially after nerve injury are being
pursued as possible neuropathic pain treatments. In a previous behavioural study, the peptide toxin Tx3-3, which blocks P/Q- and
R-type voltage-gated calcium channels, was effective in neuropathic pain models.
Objectives: In the present study, we aimed to investigate the effect of Tx3-3 on dorsal horn neuronal responses in rats under
physiological conditions and neuropathic pain condition induced by spinal nerve ligation (SNL).
Methods: In vivo electrophysiological recordings of dorsal horn neuronal response to electrical and natural (mechanical and
thermal) stimuli were made in rats under normal physiological state (naive rats) or after the SNL model of neuropathic pain.
Results: Tx3-3 (0.3–100 pmol/site) exhibited greater inhibitory effect on electrical-evoked neuronal response of SNL rats than naive
rats, inhibiting nociceptive C-fibre and Ad-fibre responses only in SNL rats. The wind-up of neurones, a measurement of spinal cord
hyperexcitability, was alsomore susceptible to a dose-related inhibition by Tx3-3 after nerve injury.Moreover, Tx3-3 exhibited higher
potency to inhibit mechanical- and thermal-evoked neuronal response in conditions of neuropathy.
Conclusion: Tx3-3mediated differential inhibitory effect under physiological and neuropathic conditions, exhibiting greater potency
in conditions of neuropathic pain.
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1. Introduction
Natural products have been historically employed in the
alleviation of pain. In recent years, the identification of drugs with
analgesic properties from animal venoms has resulted in novel
structural classes and mechanisms of actions. Voltage-gated
calcium channels (VGCCs) emerged as potential targets to treat
severe pain conditions with the advent of a peptide toxin
extracted from the venom of the cone snail Conus magus, the
v-conotoxin MVIIA, as a treatment for severe pain refractory to
other treatments.31,44,46 The v-conotoxin MVIIA (synthetic form
known as ziconotide, Prialt) produces pain relief by blocking N-
type VGCC.35
Voltage-gated calcium channels comprise a family of ion
channels divided into low-threshold (T-type) and high-threshold
(L-, N-, P/Q-, and R-type) voltage-gated channels. Based on the
sequence homology of themain pore-formed a1 subunit, VGCCs
are divided into 3 families: Cav1, Cav2, and Cav3.16 The Cav2
family includes VGCCs that carry P/Q- (Cav2.1), N- (Cav2.2), and
R-type (Cav2.3) currents. These currents are distinguishedby their
sensitivity to peptide toxins from snail and spider venoms18,36,41
and are present primarily in neurones, being involved in
neurotransmitter release and synaptic plasticity.7,8 In the spinal
cord, VGCCs are distributed among various types of neurones
and have been implicated in the spinal processing of nociceptive
transmission.57
Different subtypes of VGCC blockers have been tested in animal
models of pain, and the responsiveness of each subtype of VGCC
blockers often depends on the nature of the pain state.10,28,45,50,54
Notably, under neuropathic pain conditions, spinal N- and R-type
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calcium currents seem to play an important role.29,30 On the other
hand, spinal P/Q-type VGCCs are less implicated in dorsal horn
neuronal response after nerve damage30 but are related to central
sensitization secondary to inflammatory pain.32,33 In line with
electrophysiological studies, knockout animals have highlighted
the role of the different VGCC subtypes in transmission and
sensitization of pain.27,42,43
Recently, the peptide toxin Tx3-3, extracted from the venom of
the spider Phoneutria nigriventer was tested in a behavioural
study in rodents and showed antinociceptive effect in experi-
mental neuropathic pain rather than inflammatory pain.13 Tx3-3
blocks P/Q- and R-type VGCCs24 but induces a different profile
of behavioural effects when compared to the P/Q-blocker
v-conotoxin MVIIC, exhibiting better therapeutic window.
Although v-conotoxin MVIIC elicited serious motor dysfunctions
when injected by intrathecal (i.t.) or intracerebroventricular (i.c.v)
routes, injection of Tx3-3 induced minimal motor effects by i.c.v
route, only at doses of an order of magnitude higher than the
antinociceptive dose.13 The therapeutic window exhibited by i.t.
Tx3-3 in previous behavioural experiments (no side effects were
elicited with a dose .10 times the median effective dose)13 is
interesting in the search of clinically useful agents, given that most
of VGCC blockers studied have a narrow therapeutic win-
dow.28,39 However, whether this peptide toxin directly affects
nociceptive transmission in dorsal horn spinal cord is not known.
Furthermore, drugs that counteract the nociceptive transmission
in the spinal dorsal horn preferentially after nerve injury are being
pursued as possible neuropathic pain treatments. Therefore, the
aim of the present study was to investigate the effects of Tx3-3 on
the evoked dorsal horn neuronal responses in normal physiolog-
ical conditions and in neuropathic conditions induced by spinal
nerve ligation (SNL) in rats.
2. Materials and methods
2.1. Animals
Thirty nine male Sprague Dawley rats (Central Biologic Services,
University College London, London, United Kingdom), weighing
200–250 g, were used in this study. They were housed at
a maximum of 5 per cage on a 12-hour day/night cycle. Food and
water were available ad libitum. All experimental procedures were
approved by the UK Home Office and follow the guidelines of the
International Association for the Study of Pain for the care and use of
laboratory animals.59 Thenumber of animals usedwas theminimum
necessary to demonstrate consistent effects of drug treatments.
2.2. Toxin purification
Phoneutria nigriventer venom was obtained by electrical stimu-
lation of anesthetized spiders. The peptide toxin Tx3-3 was
purified from the venom by a combination of chromatographic
steps, as described previously.12 The criteria for the purity and
identity of the Tx3-3 are based on the shape/morphology of
the toxin peak in the final reverse phase high pressure liquid
chromatography (RP-HPLC), the results of electrospray ioniza-
tion quadrupole time-of-fly mass spectrometry (ESI/TOF MS)
mass spectroscopy, and the determination of the N-terminal
sequence of 20–20 amino acids of every sample. All of the
samples used presented a purity of better than 95%. Tx3-3 has
a molecular weight of 5100.00 Da and its aminoacid sequence is
GKCADAWESCDNYPCCVVNGYSRTCMCSANRCNCDDTKTL-
REHFG.6 Tx3-3 was stored at 220˚C and freshly diluted to
experimental doses with saline solution (NaCl 0.9%).
2.3. Spinal nerve ligation
Selective tight ligation of spinal nerves L5 and L6 was performed
as first described by Kim and Chung.23 Briefly, under gaseous
anaesthesia (isoflurane 1.5%–1.7%, delivered in a gaseousmix of
66% of N2O and 33% of O2), the rat was placed in a prone
position and a midline incision was made from L4–S2. The left
paraspinal muscles were separated from the spinous processes.
Part of the L6 transverse process was removed to expose the L4
and L5 spinal nerves, and L6 was identified lying just under the
sacrum. The left L5 and L6 spinal nerveswere isolated using glass
nerve hooks (Ski-ry Ltd, London, United Kingdom) and tightly
ligated, using 6-0 silk thread, distal to their dorsal root ganglion
and proximal to their conjunction to form the sciatic nerve.
Haemostasis was confirmed, the wound was sutured, and the
animal recovered from anaesthesia. For 2 weeks after surgery,
the rats were housed in groups of 4 in plastic cages under a
12/12-hour day/night cycle, and their general health was
monitored. The electrophysiological experiments were made at
postoperative days 14 to 17, when neuropathic pain behaviours
have been shown to be evident.11,19,30
2.4. In vivo electrophysiology
In vivo electrophysiology recordings were performed as pre-
viously described.11 Briefly, anaesthesia was induced (isoflurane
5%; 66% N2O, and 33% O2) and a cannula was inserted into the
trachea, to allow continuous anesthetic delivery along the
experiment (isoflurane 1.5%; 66% N2O, and 33% O2). This level
of anaesthesia was maintained throughout experiments that
lasted up to 9 hours. During this time the core body temperature
of the rat wasmonitored andmaintained (36·5–37˚C) bymeans of
a heating blanket connected to a rectal thermal probe via an
automatic feedback control unit. The rats breathed spontane-
ously throughout the experiment and therefore were able to
regulate their acid–base balance. A laminectomy was performed
(vertebrae L1–L3) to expose segments L4-L5 of the spinal cord.
Extracellular recordings of single deepwide dynamic range dorsal
horn neurones (500–1000 mm depth; laminae V–VI) were made
using a parylene-coated tungsten electrode (125-mm diameter,
2 MV; A-M systems). Positive wide dynamic range neurones
were identified by their ability to respond to a range of von Frey
filaments and thermal stimuli applied to the receptive field. Data
were captured and analysed by a CED 1401 interface coupled to
Spike 2 software (Cambridge Electronic Design, Cambridge,
United Kingdom).
2.5. Experimental design
The testing protocol consisted of an electrical test followed by
the natural stimuli. Electrical stimulation consisted of a train of
16 transcutaneous electrical stimuli (2 milliseconds pulse width,
0.5 Hz) applied to the receptive field at 3 times the threshold
current for C-fibre activation, which generated a post-stimulus
histogram in which responses evoked by Ab-fibre (0–20
milliseconds), Ad-fibre (20–90 milliseconds), C-fibre (90–300
milliseconds), and postdischarge (300–800 milliseconds) were
separated and quantified on the basis of latency. The number of
action potentials in the C-fibre and postdischarge range evoked
by the first stimulus of the train multiplied by the total number of
electrical stimuli (16) is referred to as input (non potentiated
response). Wind-up (potentiated response) was calculated as
the total number of action potentials in the C-fibre and
postdischarge range produced by the train of 16 stimuli minus
the input.
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Following electrical stimuli, natural stimuli, comprising dynamic
brush, mechanical punctate (application of von Frey filaments: 8,
15 and 60 g), and thermal stimuli (application of a constant water
jet at 40, 45, and 48˚C), were applied to the neuronal receptive
field for 10 seconds, and the total number of evoked spikes was
recorded. Sufficient intervals (1–2 minutes) were allowed within
and between stimuli to avoid sensitization of receptors. After 3
consecutive stable control trials (,20% variation for all param-
eters), neuronal responses were averaged to give predrug control
values with which subsequent responses were compared. Spinal
applications of Tx3-3 (0.03–100 pmol/site, in a volume of 50 mL)
were made directly onto the exposed surface of the spinal cord.
The doses of Tx3-3 used were chosen based on previous
behavioural study.13 The effect of each dose was followed for an
hour, with tests carried out at 10, 30, and 60 minutes post-drug.
One neurone per rat was recorded in each experiment. In SNL
rats, all neurones recorded had the receptive field over the left
hindpaw, ipsilateral to surgery. In naive rats, either left or right side
of spinal cord was analysed, in a counterbalanced manner.
2.6. Statistical analysis
Statistical analysis was performed using GraphPad Prism Version
5.01. One-way analysis of variance (ANOVA) with Dunnett’s post
hoc test was used in dose–response curve experiments; 2-way
ANOVA was used to access the effect of Tx3-3 on wind-up
response; Student’s paired t test was used to access the effect of
Tx3-3 on input responses; Student’s unpaired t test was used to
compare neuronal characteristics and evoked responses be-
tween naive and SNL rats. F and P values are given at maximum
peak of each significant interval; P , 0.05 were considered
significant.
3. Results
The effects of Tx3-3 applied directly onto the spinal cord on the
electrically, mechanically and thermally evoked response of deep
dorsal horn neurones were tested in naive and SNL rats. No
significant difference was found between the 2 experimental
groups in the mean cell depth of recorded neurones and the
mean baseline neuronal responses evoked by electrical, me-
chanical, and noxious thermal stimulation (Table 1), allowing
direct comparison of the effects of Tx3-3 between the 2
experimental groups.
3.1. Tx3-3 shows greater inhibition profile on electrically
evoked neuronal responses in spinal nerve ligated than
naive rats
Tx3-3 caused an inhibitory effect on the dorsal horn neuronal
responses to electrical stimulation in SNL rats and, to a far lesser
extent, in naive animals. In naive rats, Tx3-3 (30 pmol/site)
mediated statistically significant inhibitions of postdischarge
response, compared to predrug values (45 6 10% inhibition;
F(3,25) 5 3.704, P 5 0.0248), but no effect was seen on Ab, Ad,
and C-fibre responses (Fig. 1A). In SNL rats, Tx3-3 caused a
clear dose-dependent inhibition of postdischarge (50.6 6
16.08% inhibition; F(3,25) 5 3.081, P 5 0.0457), C-fibre (37.3 6
13.97% inhibition; F(3,25) 5 6.286, P 5 0.0025), and Ad-
(27.9 6 8.1% inhibition; F(3,25) 5 3.011, P 5 0.049) response,
but no effect was seen on Ab-fibre responses (F(3,25) 5 1.466,
P5 0.2477) (Fig. 1B). We also analysed the effects of Tx3-3 on
wind-up of neurones, as a measure of hypersensitivity. Tx3-3
inhibited the wind-up (increases in number of spikes evoked by
increasing stimuli number) in both naive (2-way ANOVA, F(3,240)5
22.06,P, 0.0001) and SNL rats (2-way ANOVA, F(3,240)5 28.47,
P, 0.0001), but SNL rats were more susceptible than naive rats
to the dose-dependent inhibition by Tx3-3 (Fig. 2A, B), whichwas
particularly evident by the flattening of the curve of spikes/
stimulus x electrical pulses induced by application of 30 pmol/site
of Tx3-3 (Fig. 2B). Tx3-3 (30 pmol/site) also inhibited input
(number of spikes evoked by the first stimulus of the electrical
train) in SNL rats (50.5 6 14.1% of inhibition; Paired t test, P 5
0.0064), but no difference was found in input of naive rats treated
with Tx3-3, at any dose tested (Fig. 2Aa, Bb).
3.2. Tx3-3 exhibits higher potency to inhibit naturally evoked
neuronal response in spinal nerve ligated than naive rats
When tested on a range of mechanical stimuli, Tx3-3 exhibited
higher potency to inhibit dorsal horn neuronal responses in SNL
than naive rats. Tx3-3 inhibited to the same extent neuronal
responses evoked by noxious punctate mechanical stimulation
(von Frey 26 and 60 g) in SNL and naive rats (Fig. 3A, B), but the
same level of inhibition was achieved by a 100-fold lower dose of
Tx3-3 in SNL rats (inhibition of 46.7 6 10.8% was achieved by
Tx3-3 at 0.3 pmol/site; F(4,33)5 9.781,P, 0.0001) in comparison
to naive rats (42.26 3.9%was achieved by Tx3-3 at 30 pmol/site;
F(3,26) 5 4.547, P 5 0.0109) (Fig. 3C). A leftward shift in the
dose–response curve of Tx3-3 in SNL rats in comparison to naive
rats was also seen in neuronal response evoked by nonnoxious
mechanical stimuli (von Frey 8 g). In SNL rats, a significant
inhibitory effect on neuronal response evoked by nonnoxious
punctate mechanical stimulus (von Frey 8 g) was reached by
application of 0.3 pmol/site of Tx3-3 (inhibition of 54.5 6 8.6%;
F(4,33) 5 4.294, P 5 0.0066), while 30 pmol/site of Tx3-3 was
needed to inhibit neuronal response in naive rats (inhibition of
41.76 13.7%; F(3,26)5 3.493, P5 0.0297) (Fig. 3C). Moreover,
Tx3-3 exhibited inhibitory effect on nonnoxious dynamic me-
chanical stimulation (brush) in SNL rats (inhibition of 52.2 6 8.7;
F(4,33)5 2.840, P5 0.0404), but not in naive rats (F(3,26)5 2.739,
P 5 0.0637) (Fig. 3A, B).
Neuronal responses to thermal stimulation (40, 45, and 48˚C)
were also inhibited by spinal application of Tx3-3 in naive andSNL
rats. Tx3-3 inhibited neuronal responses evoked by noxious
thermal stimulus (48˚C) in both naive (inhibition of 41 6 15%;
Table 1
Comparison of dorsal horn neuronal characteristics between
naive and SNL rats.
Measure Naive rats SNL rats
Cell depth, mm 619 6 13.5 675 6 38.3
C-fibre threshold, mA 1.2 6 0.1 1.1 6 0.09
C-fibre response (APs) 558.5 6 64.3 506.2 6 32.8
Ab-response (APs) 139.7 6 14.6 144 6 13.1
Ad-response (APs) 176.7 6 27.1 205.9 6 15.7
Post-discharge (APs) 446.7 6 38.0 545.9 6 64.5
von Frey 8 g (APs) 325.8 6 44.7 292.8 6 38.6
von Frey 26 g (APs) 918.6 6 80.8 792.9 6 55.5
von Frey 60 g (APs) 1070 6 91.8 974.3 6 54.6
48˚C heat (APs) 1152 6 81.8 1216 6 70
Data for the electrically evoked responses are expressed as the mean number of action potentials (APs) 6
SEM evoked by a train of 16 electrical stimuli at 3 times the threshold for C-fibres. Data of mechanical and
thermal stimuli are expressed as the number of APs evoked during the 10-second period for which the
stimulus was applied to the cell’s peripheral receptive field. Data were analysed using Student unpaired t test.
SNL, spinal nerve ligated.
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F(3,23) 5 3.324, P 5 0.0375) and SNL rats (inhibition of 38.7% 6
7.6; F(3,25)5 6.912, P5 0.00015) (Fig. 3D, E). In SNL rats, Tx3-3
mediated a broader inhibition of neuronal response to thermal
stimulus, inhibiting also the responses evoked by 40˚C (inhibition
of 62.5% 6 11.6; F(3,25) 5 4.532; P 5 0.0118). Moreover, lower
doses of Tx3-3 were required to achieve significant inhibition in
SNL rats than in naive rats (Fig. 3D, E).
Overall, the maximum inhibitions produced by Tx3-3 were
established around 10 to 20 minutes, and the inhibitory effect
lasted approximately 60 minutes (Appendix). No difference was
found in timecourse effect of Tx3-3 between naive and SNL rats
(data not shown).
4. Discussion
In this study, we addressed the effect of the peptide toxin Tx3-3,
a P/Q- and R-type VGCC blocker, in in vivo electrophysiological
measurements of dorsal horn neuronal responses under
physiological and neuropathic conditions. We showed that Tx3-
3 mediated differential inhibitory effect on deep dorsal horn
neuronal responses under physiological and neuropathic con-
ditions, exhibiting greater potency after nerve injury.
When tested on neuronal responses evoked by electrical
stimulation, Tx3-3 exhibited a greater inhibitory profile in SNL than
in naive rats. Under neuropathic conditions, Tx3-3 inhibited Ad,
C-fibre, and input responses as well as postdischarge response,
while only postdischarge was inhibited in normal animals.
Moreover, Tx3-3 produced a greater inhibition of neuronal
wind-up in SNL than naive rats. The VGCCs targeted by Tx3-3
are differentially expressed in dorsal horn spinal neurones. P/Q-
type VGCCs are expressed on nerve terminals of nonpeptidergic
IB4-positive C-fibres, while R-type VGCCs are predominantly
localized to somatodendritic compartments51 but are also
expressed on nerve terminals of peptidergic C-fibres and Ad-
fibres.17 Subcellular localization functionally link VGCC subtypes
with specific neuronal processes. P/Q-type VGCCs are involved
in initiating the release of neurotransmitters at presynaptic
sites,7,9 while R-type VGCCs play minor role in basal neurotrans-
mitter release, being involved in presynaptic mechanisms of
plasticity.5,14,53 The inhibition of synaptic transmission through
inhibition of neurotransmitter releasemay account for the effect of
Tx3-3 on postdischarge and wind-up responses evoked by
electrical stimulation in physiological conditions. In agreement,
the blockade of spinal P/Q-type VGCCs by application of
v-agatoxin-IVA in rats attenuated both postdischarge and
wind-up neuronal responses.30 However, the inhibitory profile
ofv-agatoxin-IVA remained unchanged after SNL.30 Keeping this
in mind, the differential effect mediated by Tx3-3 in neuropathic
conditions is thus unlikely to be mediated by its action on P/Q-
type VGCCs. Furthermore, classically, P/Q-type VGCC blockers
present modest effects against neuropathic pain.10,50,55 In-
terestingly, the inhibitory profile of Tx3-3 on electrically evoked
neuronal responses resemble those elicited by the R-type VGCC
blocker SNX-482.29 Both Tx3-3 and SNX-482, a peptide isolated
from the venom of the spider Hysterocrates gigas,34 inhibited
postdischarge and wind-up responses under control conditions,
but exhibited a greater inhibitory profile in neuropathic conditions
induced by SNL, inhibiting also nociceptive C-fibre and Ad-fibre
responses.29 Moreover, like SNX-482, the input and wind-up
responses were rather affected by Tx3-3 after neuropathy.
Thus the effect of Tx3-3 on electrically evoked dorsal horn
neuronal responses in neuropathic conditions are consistent with
amajor blockade of R-type VGCCs. In the SNL animals, thewind-
up profile differed from that in the control group as the initial
response, an index of presynaptic mechanisms delivering the
input onto the neurones, was markedly increased, perhaps
indicative of enhanced presynaptic spinalmechanisms in keeping
with the augmented effects of the toxin after neuropathy.
The antinociceptive properties of Tx3-3 were previously shown
in neuropathic pain models of sciatic nerve ligation and diabetic
neuropathy.13 In the present study, we have addressed the effect
of Tx3-3 in in vivo electrophysiology recordings of dorsal horn
neurones after the SNL model of chronic neuropathic pain.23 In
line to the earlier behavioural study, in which Tx3-3 attenuated the
tactile allodynia induced by traumatic neuropathy,13 here we
show that Tx3-3 inhibits dorsal horn neuronal response evoked
by innocuous mechanical stimulation in SNL rats. Despite the
effect on innocuous mechanical response, Tx3-3 did not affect
Ab-fibres responses. However, electrically evoked responses are
suprathreshold and syncronious; by contrast, natural stimuli
evoked by 8 g von Frey stimulation applied over 10 seconds are
more amenable to inhibition and are likely to activate also
Figure 1. Dose–response curve of Tx3-3 on the electrically evoked neuronal
responses recorded from naive (A) and SNL (B) rats. Ab-fibre (Ab), Ad-fibre
(Ad), C-fibre (C) and postdischarge (PD) measurements are shown. Data are
expressed as mean maximum inhibition response during the first hour after
drug application onto spinal cord of rats (50 mL/site) 6 SEM. In spinal nerve
ligation rats, the neuronal response was evaluated 14 to 17 days after surgery.
Each column represents the mean response of 5 to 7 neurones. Vertical lines
show the SEM. Statistical analysis was determined using 1-way analysis of
variance followed byDunnett’s post hoc test. Asterisks denote the significance
levels in comparison to predrug value, *P , 0.05, **P , 0.01.
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Ad-fibres, which could explain this effect. Importantly, we show
that mechanically evoked dorsal horn responses were more
sensitive to Tx3-3 in conditions of neuropathy. The higher potency
of Tx3-3 in SNL rats suggests a higher affinity of Tx3-3 to VGCC
after neuropathy. It has been shown that in neuropathic states the
high frequency of fiber activation produces a dynamic change in
the VGCC conformational state, switching between resting,
activated, and inactivated state.1 The access to the inactivated
channel is greater during high-frequency neuronal firing conditions,
improving the affinity of certain VGCC blockers, as occurring with
Figure 2. Effect of spinally applied Tx3-3 on the electrically evoked neuronal wind-up and input responses recorded from naive (A, Aa) and spinal nerve ligation
(B, Bb) rats. Data are expressed as mean number of spikes evoked per stimulus of the electrical train of 16 stimuli (wind-up; A, B) and mean number of spikes
evoked by the first stimulus of the electrical train3 16 (input; Aa, Bb)6 SEM. Each point or column represents themean response of 5 to 7 neurones. Vertical lines
show the SEM. Statistical analysis was determined using 2-way analysis of variance for wind-up response (A, B) and paired t test for input response (Aa, Bb).
Asterisks denote the significance levels in comparison to predrug values, **P , 0.01, ***P , 0.001.
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somev-conotoxins that exhibit higher potencywhenbinding to the
inactivated state of VGCC.3,47,52,58 Such state-dependent block-
ade property could account for themore potent blockade of Tx3-3
during the higher frequency of spontaneous neuronal firing present
after SNL.11 The higher magnitude of inhibition and dose-related
effect of Tx3-3 on wind-up responses in neuropathic rats further
support the notion that the reorganization of VGCCs kinetics
properties following nerve damage favors the Tx3-3 binding. In this
regard, it is noteworthy that neuronal responses evoked by
nonnoxious thermal and mechanical stimuli were sensitive to
Tx3-3 inhibition preferentially in neuropathic conditions, indicating
an enhanced excitability of spinal transmission from afferents that
expressedTx3-3-sensitive VGCCsafter neuropathy. In agreement,
dorsal horn neuronal response evoked by nonnoxious punctate
mechanical stimulus is more sensitive to the R-type VGCC blocker
SNX-482 in neuropathic conditions.29 Furthermore, P/Q-type
VGCCs are also found in the deeper laminae of the dorsal horn,51
suggesting its presence on touch-sensitive large fibres, and there
are reports of increased levels of P/Q-type in DRG, especially in
medium and large myelinated afferent fibers, in neuropathic pain
models.49,56 Thus, nerve injury may establish a functional re-
organization of neuronal phenotypes within the spinal cord, by
changing thepattern of expression or activity of some ion channels,
including the VGCCs target by Tx3-3, which explains the outcome
effect of Tx3-3 onneuronal response evoked by nonnoxious stimuli
in neuropathic rats.
Figure 3. Dose–response curve of Tx3-3 on naturally evoked neuronal responses recorded from naive (A, D) and spinal nerve ligation (SNL) (B, E) rats. Evoked
dorsal horn neuronal response to mechanical (A, B) and thermal (D, E) stimuli and dose–response curve of Tx3-3 in naive and SNL rats (C) are shown. Data are
expressed as mean maximum inhibition response during the first hour after drug application onto spinal cord of rats (50 mL/site)6 SEM. In SNL rats the neuronal
response was evaluated 14 to 17 days after surgery. Each point represents themean response of 5 to 7 neurones. Vertical lines show the SEM. Statistical analysis
was determined using 1-way analysis of variance followed by Dunnett’s post hoc test for eachmechanical and thermal stimulus. Asterisks denote the significance
levels in comparison to predrug values, *P , 0.05, **P , 0.01, ***P , 0.001.
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It is also worth mentioning the possible role of the auxiliary a2d
subunit of VGCCs in our current results. The a2d subunits of
VGCCs (comprises a2d-1, a2d-2, a2d-3, and a2d-4) regulate
VGCC biophysical properties, trafficking, and membrane expres-
sion2,15,22 and are upregulated in the dorsal horn spinal cord,
mediating spinal hyperexcitability, under neuropathic condi-
tions.4,25,26 Recently it was shown that the disruption of the
a2d1 gene expression leads to a delay in development of
mechanical hypersensitivity in neuropathicmice, which correlates
with a reduction in the response of deep dorsal horn neurones to
a range of mechanical stimuli.37 Which subtype of Cav2 family is
mainly affected by a2d regulation in neuropathic conditions
remains to be clearly defined. However, most aspects of the R-
type pore-forming a1 subunit (alpha 1E) are affected by a2d
regulation, including the kinetics of activation-inactivation-
deactivation of R-type VGCCs,40 and the trafficking of Cav2.1
(which conducts P/Q-type currents) to cell surface is prevented
bymutation in thea2d2 subunits.20,21 Therefore, it is possible that
the adaptations on VGCC function and expression carried out by
a2d subunits in neuropathic conditions underlie the gain of effect
of Tx3-3.
The Tx3-3 affected the neuronal responses evoked by
thermal stimulation in naive and SNL rats. These results are in
accordance with the previously reported inhibitory effect of Tx3-
3 in heat-induced nociceptive pain.13 Notably, the doses of Tx3-
3 used here are comparable to those used in the above-
mentioned behavioral study. In the present study, however, the
lower dose of Tx3-3 showed a tendency to increase the
thermally evoked neuronal response in naive rats. This may
result from the blockade of P/Q-type VGCCs presented on
inhibitory interneurones.48,51 Likewise, spinal application of the
P/Q-type VGCC blocker v-agatoxin IVA tended to facilitate
neuronal responses at lower doses.30 However, this phenom-
enon was not seen in SNL rats, possibly because in this
neuropathic condition, R-type VGCCs come into play, as
demonstrated by the increased sensitivity of thermally evoked
neuronal response to the R-type VGCC blocker SNX-482 in SNL
rats.29 Therefore, possibly, the neuropathy may cause a path-
ophysiological upregulation of R-type VGCC activity (or promote
a given conformational state) that favors the action of Tx3-3 on
it, explained by the enhanced sensitivity of SNL rats to Tx3-3
inhibitory effect on thermally evoked neuronal responses (as
lower doses were needed to achieve inhibitory effect in SNL rats
compared to control rats).
This is the first electrophysiological study addressing the
effects of Tx3-3 on sensory transmission in spinal cord of rats.
The present data extend results from previous behavioural
studies, showing a prevalent antinociceptive effect of Tx3-3 on
neuropathic states and suggest the R-type VGCC as the main
target of such action.
5. Concluding remarks
A significant functional role of VGCCs in neuropathic pain
mechanisms has been substantiated by studies using toxins
isolated from animal venoms.38,54 Here, we showed that the toxin
Tx3-3, a P/Q- and R-type VGCC blocker isolated from the venom
of the spider P. nigriventer, mediated differential inhibitory effect
on deep dorsal horn neuronal responses under physiological and
neuropathic pain conditions, exhibiting greater potency after
nerve damage. The profile of action of Tx3-3 highlights the role of
VGCCs, drawing attention to R-type VGCC, in pathological pain
and may provide insight into the development of specific
analgesics for the treatment of neuropathic pain.
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